CD274 and hepatocellular carcinoma: To our best knowledge, the current study combined 28ζ CAR modification and the CRISPR-mediated disruption of endogenous inhibitory immune checkpoint receptor PD-1 in adoptive T cell immunotherapy of native PD-L1-expressing HCC for the first time.